Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

39.26 +0.45 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
27 28 Next >
Hopes For A Peace Accord
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
Biogen Posts New Updates Across its Spinraza SMA Research Program
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and... 
Via Benzinga
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities. 
Via Investor's Business Daily
OTC Markets 2021 Annual Data Review Highlights A Record 60% $ Volume Increase
Photo by Sophie Bakes on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The... 
Via Benzinga
The Ruble Is Rubble
MSCI says Russian companies are 
Via Talk Markets
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Holiday Over
China is busily avoiding taking sides between Ukraine and Russia. 
Via Talk Markets
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
Why Are Seagen Shares Sinking Today?
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues 
Via Benzinga
Dampening Exuberance
The bond sell-off halted today but the Fed's plans mean this will resume. 
Via Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came... 
Via Talk Markets
Global Diversification: Switzerland And The Philippines
One way to avoid or defend against slowing growth in the US is to own positions in other countries. There is likely a fund for almost any developed country you can think of that owns a basket of stocks... 
Via Talk Markets
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed. 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
A News Blizzard
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests
Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH 
Via Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,  
Via Benzinga
World Markets News for Tuesday
Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon. 
Via Talk Markets
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
Biogen Inc (NASDAQ: BIIB) has  
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo
The FDA has approved Genentech's, a unit of  
Via Benzinga
FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
Drug Troubles
The drug sector has both good news and bad. 
Via Talk Markets
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.